Immuneering (IMRX) Cash from Investing Activities (2020 - 2026)

Immuneering's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$63.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 704995.3% year-over-year to -$63.1 million; the TTM figure through Mar 2026 stood at -$151.8 million (down 3115.8% YoY), while the FY2025 annual figure was -$88.7 million, down 435.69% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$63.1 million, up from -$88.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $22.2 million in Q2 2022, with the low at -$88.7 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $3.1 million (2023), against an average of -$4.5 million.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities jumped 111852.97% in 2022, then slumped 704995.3% in 2026.
• Immuneering's Cash from Investing Activities stood at $8.2 million in 2022, then plunged by 61.57% to $3.1 million in 2023, then soared by 75.26% to $5.5 million in 2024, then tumbled by 1715.84% to -$88.7 million in 2025, then gained by 28.91% to -$63.1 million in 2026.
• Business Quant data shows IMRX's Cash from Investing Activities at -$63.1 million in Q1 2026, -$88.7 million in Q4 2025, and -$7255.0 in Q3 2025.